Glucocorticoid-Induced Osteoporosis: Increased Awareness as a Management Strategy for Prevention of this Complication in Patients with Systemic Autoimmune Rheumatic Disease

Background: It has been estimated that about 1% of the US population is treated with long-term glucocorticoids. High doses of glucocorticoids particularly those used by rheumatologists and others for systemic autoimmune rheumatic disease result in bone loss, causing glucocorticoid-induced osteoporos...

Descripción completa

Detalles Bibliográficos
Autores principales: Bankole, Adegbenga, Greear, Emma L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mesut Onat 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543380/
https://www.ncbi.nlm.nih.gov/pubmed/37681255
http://dx.doi.org/10.5152/eurjrheum.2023.22086

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543380/
https://www.ncbi.nlm.nih.gov/pubmed/37681255
http://dx.doi.org/10.5152/eurjrheum.2023.22086

Ejemplares similares